Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia Jun 25, 2024 07:00AM
Quince Therapeutics (QNCX) Receives FDA Fast Track Designation for EryDex System Jun 3, 2024 07:00AM
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System Jun 3, 2024 07:00AM
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results May 13, 2024 07:00AM
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference May 6, 2024 04:05PM


Apr 1, 2024 07:00AM Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
Feb 22, 2024 07:01AM Quince Therapeutics (QNCX) Launches Scientific Advisory Board
Feb 22, 2024 07:00AM Quince Therapeutics Launches Scientific Advisory Board
Feb 15, 2024 07:03AM Quince Therapeutics (QNCX) Appoints Rajiv Patni to its Board
Feb 15, 2024 07:00AM Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
Feb 7, 2024 04:05PM Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 4, 2024 04:05PM Quince Therapeutics to Participate at Investor Events in January 2024
Sep 28, 2023 04:05PM Quince Therapeutics (QNCX) Announces FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Sep 28, 2023 04:05PM U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Sep 6, 2023 07:03AM Quince Therapeutics (QNCX) Appoints Charles S. Ryan as President
Sep 6, 2023 07:00AM Quince Therapeutics Appoints Dr. Charles S. Ryan as President
Aug 10, 2023 04:05PM Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
Jul 24, 2023 07:04AM Quince Therapeutics (QNCX) to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia
Jul 24, 2023 07:00AM Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
Apr 11, 2023 07:01AM Quince Therapeutics (QNCX) Board Unanimously Rejects Unsolicited $1.60/sh Acquisition Proposal from Echo Lake Capital
Apr 11, 2023 07:00AM Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital
Apr 6, 2023 04:05PM Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor
Apr 5, 2023 04:06PM Quince Therapeutics (QNCX) Adopts Limited Duration Stockholders Rights Plan
Apr 5, 2023 04:05PM Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
Mar 22, 2023 05:53AM Quince Therapeutics (QNCX) Confirms Unsolicited $1.60/sh Acquisition Offer from Echo Lake Capital
Mar 22, 2023 05:00AM Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
Jan 30, 2023 04:05PM Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
Jan 27, 2023 08:42AM Quince Therapeutics (QNCX) Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
Jan 27, 2023 08:00AM Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
Sep 16, 2022 08:03AM (QNCX) Presents Preclinical Data Demonstrating Efficacy of Bone-targeting Platform for Traumatic Bone Injury
Sep 16, 2022 08:00AM Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury
Sep 12, 2022 08:00AM Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications
Aug 30, 2022 04:05PM Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures
Aug 25, 2022 04:05PM Quince Therapeutics to Present at Upcoming Scientific Meetings
Aug 4, 2022 08:00AM Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022
Aug 1, 2022 08:13AM Quince Therapeutics (QNCX) Details Strategic Growth Plan with Launch of New Corporate Name
Aug 1, 2022 08:00AM Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
Jul 27, 2022 08:01AM Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022